Best Dividend Aristocrats For September 2026

Dividend Aristocrats, tracked via NOBL, delivered a 12.9% YTD return, closely trailing SPY's 13.68%, with 29 Aristocrats outperforming SPY in 2026. Top 2026 performers include TGT (+73.04%), NUE (+55.64%), and BEN (+49.25%), highlighting strong sectoral momentum among select Aristocrats. Six Aristocrats announced dividend increases in the past month, pushing the group's average 2026 dividend growth rate to 4.30%, up from 4.10% last month.

Seeking Alpha • Aug 28, 2026

West to Participate in Upcoming Investor Conferences

EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Wells Fargo Annual Healthcare Conference on Thursday, September 10, 2026 at 8:45 a.m. EDT in Everett, MA Morgan Stanley Annual Global Healthcare Conference on Monday, September 14, 2026 at 8:30 a.m.

PRNewsWire • Aug 26, 2026

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Aug 14, 2026

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

Zacks Investment Research • Aug 14, 2026

WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story

West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.

Zacks Investment Research • Aug 13, 2026

WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook

WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.

Zacks Investment Research • Aug 13, 2026

Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.

Zacks Investment Research • Aug 13, 2026

Top 50 High-Quality Dividend Growth Stocks For August 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. The universe delivered a 10.44% YTD return through July, closely matching SPY but trailing SCHD, with several individual stocks significantly outperforming. Currently, 40 stocks in the universe offer a forward return estimate of at least 10%, with 25 appearing potentially undervalued based on free cash flow analysis.

Seeking Alpha • Aug 9, 2026

Conestoga SMid Cap Composite Q2 2026 Portfolio Review

West Pharmaceuticals stock moved higher following another quarter of broad-based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Tyler Technologies underperformed during the quarter despite delivering solid financial results that met management's guidance. We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.

Seeking Alpha • Jul 31, 2026

Best Dividend Aristocrats For August 2026

NOBL is outperforming SPY YTD in 2026, returning 12.9% versus SPY's 7.88%, with 45 Aristocrats ahead of SPY. Dividend growth among Aristocrats in 2026 averages 4.10%, with recent increases from ALB, FAST, PPG, SJM, and SWK. 25 Dividend Aristocrats appear undervalued and offer estimated long-term annualized returns of at least 10% using dividend yield theory.

Seeking Alpha • Jul 29, 2026